Innate Pharma (IPHA) Stock Statistics & Valuation Metrics

Innate Pharma has a market cap or net worth of $204.84M. The enterprise value is ―.

Innate Pharma has 92,176,380 shares outstanding. The number of shares has decreased by -2.65% in one year.

Innate Pharma’s return on equity (ROE) is -0.15 and return on invested capital (ROIC) is -8.25%.

The current PE Ratio of Innate Pharma is -26.92. Innate Pharma’s PEG ratio is 0.01.

In the last 12 months, Innate Pharma had revenue of 51.90M and earned -7.57M in profits. Earnings per share was -0.09.

In the last 12 months, operating cash flow was -18.06M and capital expenditures -325.00K, giving a free cash flow of -18.38M billion.

Innate Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

Innate Pharma upcoming earnings date is Sep 17, 2025, TBA Not Confirmed.

Innate Pharma as a current ratio of 3.73, with Debt / Equity ratio of 123.29%

In the past 12 months, Innate Pharma has paid 0.00 in taxes.

Innate Pharma EV to EBITDA ratio is -94.12, with an EV/FCF ratio of -4.96.

Innate Pharma has $91.80M in cash and marketable securities with €35.50M in debt, giving a net cash position of -$56.30M billion.

Gross margin is -58.77%, with operating margin of -24.41%, and net profit margin of -14.59%.

The average price target for Innate Pharma is $11.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy